Spring til indhold
Radio Logo
PodcastsBiovidenskabBusiness Of Biotech

Business Of Biotech

Ben Comer
Seneste episode

333 episoder

  • Business Of Biotech

    Preparing For Commercial Launch In Oncology With Candel Therapeutics' Paul Peter Tak, M.D., Ph.D.

    16.11.2026 | 55 min.
    We love to hear from our listeners. Send us a message.
    On this week's episode of the Business of Biotech, Paul Peter Tak, M.D., Ph.D., CEO at Candel Therapeutics, talks about the path from Phase 3 data to BLA submission for aglatimagene in localized prostate cancer and why “in situ immunization” could change how solid tumors are treated. He also talks through leadership and operating choices for minimizing risk in late-stage development, how FDA's Fast Track and RMAT designations aided communication and CMC planning, and how an outsourced commercial model can help companies prepare for launch and avoid premature fixed costs. 
    UPDATE (11/18/26): Candel Therapeutics recently became aware that the validation of the IU Assay will cause a six month delay in the completion of the BLA submission for aglatimagene, which is now expected mid-2027. 
    Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.  
    Subscribe to our monthly Business of Biotech newsletter.

    Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com

    Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
  • Business Of Biotech

    Managing Risk And Development In A Growing Neuroscience Portfolio With AbbVie's Sean Kelley

    09.11.2026 | 50 min.
    We love to hear from our listeners. Send us a message.
    On this week's episode of the Business of Biotech, Sean Kelley, Vice President for neuroscience and toxins, Portfolio Strategy and Program Leadership at AbbVie, talks through the development factors that determine whether a promising discovery becomes a medicine that reaches patients. Sean shares details about his neuroscience portfolio strategy at AbbVie, and how biomarkers in clinical development, plus dosing and formulation, can matter as much as the molecule itself. He also discusses partnering in China, and the potential for psychedelics in treating psychiatric disorders, including bretisilocin, AbbVie's first psychedelic clinical program. 

    Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.  
    Subscribe to our monthly Business of Biotech newsletter.

    Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com

    Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
  • Business Of Biotech

    Translating A New Discovery Into A Novel Cancer Therapy With Grid Therapeutics' Ned Patz, M.D.

    02.11.2026 | 53 min.
    We love to hear from our listeners. Send us a message.
    On this week's episode of the Business of Biotech, Edward (Ned) Patz, M.D., Cofounder and CEO at Grid Therapeutics, explains how a Duke University lab discovery turned into Grid Therapeutics and two clinical-stage cancer immunotherapy programs. Ned talks about discovering the human-derived antibody treatment GT103 and novel Compliment Factor H (CFH) target, the messy realities of funding a new therapeutic approach in cancer, and the leadership lessons that come with running a scrappy virtual biotech.  
    Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.  
    Subscribe to our monthly Business of Biotech newsletter.

    Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com

    Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
  • Business Of Biotech

    Bioprinting 3D Human Tissue To Discover And Test New Treatments With Viscient Bio's Keith Murphy

    26.10.2026 | 56 min.
    We love to hear from our listeners. Send us a message.
    On this week's episode of the Business of Biotech, Keith Murphy, CEO at Viscient Biosciences, unpacks how 3D human tissue models and scaffold-free bioprinting can change the way developers predict drug safety and model disease. Keith traces his professional journey from MIT and Amgen, to founding Organovo and building Viscient and VivoSim (formerly Organovo) into companies that push New Approach Methodologies (NAM) adoption and smarter, more efficient drug development. Keith also shares policy ideas the FDA could use to further incentivize the use of NAMs.
    Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.  
    Subscribe to our monthly Business of Biotech newsletter.

    Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com

    Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
  • Business Of Biotech

    Investing In Tomorrow's CNS Breakthroughs With Breyer Capital's Bret Bostwick, M.D.

    19.10.2026 | 47 min.
    We love to hear from our listeners. Send us a message.
    On this week's episode of the Business of Biotech, Bret Bostwick, M.D., Venture Partner at Breyer Capital, a family office, talks about his path from medical geneticist to CNS drug development and biotech investing. Bret reflects on lessons he learned at Alnylam about the power of genetically validated drug targets and the importance of team culture, why CNS drug development fails so often, and the problem with animal models. He also talks about where AI is truly helping early-stage biotechs, and where it can create problems. 
    Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.  
    Subscribe to our monthly Business of Biotech newsletter.

    Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com

    Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
Flere Biovidenskab podcasts
Om Business Of Biotech
The Business of Biotech is the pod dedicated to leaders of emerging biopharma firms. SUBSCRIBE to our new newsletter at www.bioprocessonline.com/bob. We bring you insight into organizational, finance and funding, HR, clinical, manufacturing, regulatory, and commercial challenges you’ll face as you navigate your company from an idea to success in the clinic and beyond. Each episode features guest commentary and best practices from accomplished founders and biopharma industry luminaries. The Business of Biotech is produced by Life Science Connect.
Podcast-websted

Lyt til Business Of Biotech, HæmatoLOGIK og mange andre podcasts fra hele verden med radio.dk-appen

Hent den gratis radio.dk-app

  • Bogmærke stationer og podcasts
  • Stream via Wi-Fi eller Bluetooth
  • Understøtter Carplay & Android Auto
  • Mange andre app-funktioner
Business Of Biotech: Podcasts i samme familie